all the information, none of the junk | biotech • healthcare • life sciences

Debt, Equity Deals for Pathogenetix

Xconomy Boston — 

Woburn, MA-based biotech Pathogenetix, formerly known as U.S. Genomics, has raised $1.3 million in equity-based funding, and $900,000 of a planned $1.2 million debt-based offering, according to filings with the SEC. U.S. Genomics developed biodefense and diagnostic technologies, and raised $4.5 million in private equity funding from Becton, Dickinson & Co in 2008, as part of a strategic partnership for pursuing diagnostics for infectious diseases. Pathogenetix has not yet returned a call seeking comment on the newest funding and the company name change.